Last reviewed · How we verify
Ad5 CEA Vaccine
At a glance
| Generic name | Ad5 CEA Vaccine |
|---|---|
| Sponsor | NantCell, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (PHASE2)
- QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA (PHASE1, PHASE2)
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (PHASE1, PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1, PHASE2)
- QUILT-3.088: NANT Pancreatic Cancer Vaccine (PHASE2)
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad5 CEA Vaccine CI brief — competitive landscape report
- Ad5 CEA Vaccine updates RSS · CI watch RSS
- NantCell, Inc. portfolio CI